Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 4/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19876769 | 1.00 | FPR2 (0.42) | FPR2ADORA2AADORA1 | |
| SCHEMBL19876768 | 1.00 | FPR2 (0.42) | FPR2ADORA2AADORA1 | |
| SCHEMBL19876782 | 0.90 | FPR2 (0.45) | FPR2 | |
| SCHEMBL19876780 | 0.90 | FPR2 (0.45) | FPR2 | |
| SCHEMBL19877943 | 0.90 | FPR2 (0.45) | FPR2 | |
| SCHEMBL19876987 | 0.76 | FPR2 (0.35) | FPR2 | |
| SCHEMBL19877315 | 0.76 | FPR2 (0.35) | FPR2 | |
| SCHEMBL19876988 | 0.76 | FPR2 (0.35) | FPR2 | |
| SCHEMBL19890161 | 0.63 | — | — | |
| SCHEMBL25025809 | 0.63 | FPR2 (0.33) | FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161824-B2 | Heterocyclic lipoxin analogs and uses thereof | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2021-11-02 | — | — | US | disclosed |
| US-11161824-B2 | Heterocyclic lipoxin analogs and uses thereof | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2021-11-02 | — | — | US | disclosed |
| EP-3500559-B1 | HETEROCYCLIC LIPOXIN ANALOGS AND USES THEROF | UNIV COLLEGE DUBLIN NAT UNIV IRELAND DUBLIN (IE) | 2021-06-16 | — | — | EP | disclosed |
| EP-3500559-B1 | HETEROCYCLIC LIPOXIN ANALOGS AND USES THEROF | UNIV COLLEGE DUBLIN NAT UNIV IRELAND DUBLIN (IE) | 2021-06-16 | — | — | EP | disclosed |
| US-20210053927-A1 | Heterocyclic Lipoxin Analogs and Uses Thereof | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2021-02-25 | — | — | US | disclosed |
| US-20210053927-A1 | Heterocyclic Lipoxin Analogs and Uses Thereof | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2021-02-25 | — | — | US | disclosed |
| EP-3500559-A1 | HETEROCYCLIC LIPOXON ANALOGS AND USES THEROF | University College Dublin (IE) | 2019-06-26 | — | — | EP | disclosed |
| WO-2018033642-A9 | HETEROCYCLIC LIPOXIN ANALOGS AND USES THEREOF | UNIVERSITY COLLEGE DUBLIN (IE) | 2018-10-18 | — | — | WO | disclosed |
| WO-2018033642-A1 | HETEROCYCLIC LIPXON ANALOGS AND USES THEROF | UNIVERSITY COLLEGE DUBLIN (IE) | 2018-02-22 | — | — | WO | disclosed |
| WO-2018033642-A1 | HETEROCYCLIC LIPXON ANALOGS AND USES THEROF | UNIVERSITY COLLEGE DUBLIN (IE) | 2018-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161824-B2 | Heterocyclic lipoxin analogs and uses thereof | LTB4R2, ALOX12, ALOX15B | FPR2 13/4885ADORA2A 793/4885ADORA1 1032/4885 |
| US-20210053927-A1 | Heterocyclic Lipoxin Analogs and Uses Thereof | LTB4R2, ALOX12, ALOX15B | FPR2 13/4885ADORA2A 793/4885ADORA1 1032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.